Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.45 |
| ▸ | TUBB | P07437 | 6/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL770174 | 0.99 | MEN1 (0.52) | MEN1KMT2ABRAFUSP2TUBB4A | |
| SCHEMBL786505 | 0.83 | TUBB1 (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL786597 | 0.83 | TUBB1 (0.52) | USP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL725347 | 0.80 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25478528 | 0.79 | TUBB1 (0.43) | USP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL19221052 | 0.78 | TUBB1 (0.37) | USP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL19214630 | 0.77 | MEN1 (0.53) | MEN1KMT2ABRAFUSP2TUBB4A | |
| SCHEMBL725066 | 0.77 | TUBB1 (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL721918 | 0.77 | HPGDS (0.54) | MEN1KMT2A | |
| SCHEMBL19221058 | 0.77 | TUBB1 (0.41) | USP2TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793549-A1 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3793548-A1 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | claimed |
| WO-2021041744-A1 | RYL BENZOYL IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF LUNG CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-03-04 | — | — | WO | claimed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | claimed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | claimed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-119548495-A | Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses | 维鲁公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4504183-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | Veru Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118984703-A | Methods of treating influenza and poxvirus infections | 维鲁公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | VERU INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885BRAF 5/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885BRAF 5/4885 |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | IL1B, PYCARD, TUBB1 | MEN1 4618/4885KMT2A 3898/4885BRAF 3091/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885BRAF 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.